FGF19 and metabolic dysfunction-associated steatohepatitis: Tropifexor is another FXR agonist first evaluated in animal models for cholestatic liver diseases and NASH.25 It has been shown to mitigate hepatic inflammation, steatosis, and reduce gamma-glutamyl transferase (GGT) levels in a dose-dependent manner with correlated increases in fibroblast growth factor-19 (FGF-19) levels.